{
  "ticker": "NVO",
  "companyName": "Novo Nordisk A/S",
  "industry": "Drug Manufacturers - General",
  "sector": "Healthcare",
  "exchange": "NYSE",
  "lastUpdated": "2025-07-19",
  "currency": "DKK",
  "currencyNote": "Financial data is in Danish Kroner (DKK). Current exchange rate: 1 USD = ~6.9 DKK",
  "exchangeRate": {
    "usdToDkk": 6.9,
    "dkkToUsd": 0.1449,
    "note": "1 USD = 6.9 DKK, 1 DKK = 0.1449 USD"
  },
  
  "marketData": {
    "currentPrice": 64.31,
    "currentPriceCurrency": "USD",
    "marketCap": 287380000000,
    "marketCapCurrency": "USD",
    "enterpriseValue": 299430000000,
    "sharesOutstanding": 4440000000,
    "beta": 0.22,
    "52WeekLow": 57.00,
    "52WeekHigh": 139.74,
    "priceTarget": 112.00,
    "analystRating": "Buy",
    "dataAsOf": "2025-07-18",
    "note": "Market data includes TTM financial metrics. Company is Denmark-based with primary financial reporting in DKK"
  },

  "riskFactors": {
    "riskFreeRate": 0.045,
    "marketRiskPremium": 0.06,
    "equityRiskPremium": 0.082,
    "countryRiskPremium": 0.005,
    "smallCompanyPremium": 0.0,
    "specificRiskPremium": 0.015
  },

  "financialHistory": {
    "TTM": {
      "revenue": 303141000000,
      "grossProfit": 256607000000,
      "operatingIncome": 146824000000,
      "netIncome": 104615000000,
      "freeCashFlow": 79133000000,
      "operatingCashFlow": 131245000000,
      "capex": 52112000000,
      "totalAssets": 489162000000,
      "totalDebt": 118723000000,
      "cashAndEquivalents": 41550000000,
      "shareholdersEquity": 138540000000,
      "bookValuePerShare": 31.21,
      "eps": 23.51,
      "dividend": 11.40,
      "workingCapital": -61722000000,
      "totalEquity": 138540000000,
      "retainedEarnings": 137319000000,
      "period": "Trailing Twelve Months as of Q2 2025",
      "reportingDate": "2025-07-19",
      "currency": "DKK"
    },
    "2024": {
      "revenue": 290403000000,
      "grossProfit": 246843000000,
      "operatingIncome": 139879000000,
      "netIncome": 100988000000,
      "freeCashFlow": 73804000000,
      "operatingCashFlow": 120968000000,
      "capex": 47164000000,
      "totalAssets": 465795000000,
      "totalDebt": 102787000000,
      "cashAndEquivalents": 26308000000,
      "shareholdersEquity": 143486000000,
      "bookValuePerShare": 32.31,
      "eps": 22.67,
      "dividend": 11.40,
      "workingCapital": -56631000000,
      "totalEquity": 143486000000,
      "retainedEarnings": 144448000000,
      "currency": "DKK"
    },
    "2023": {
      "revenue": 232261000000,
      "grossProfit": 196942000000,
      "operatingIncome": 104698000000,
      "netIncome": 83683000000,
      "freeCashFlow": 83102000000,
      "operatingCashFlow": 108908000000,
      "capex": 25806000000,
      "totalAssets": 314486000000,
      "totalDebt": 27006000000,
      "cashAndEquivalents": 30230000000,
      "shareholdersEquity": 106561000000,
      "bookValuePerShare": 23.90,
      "eps": 18.67,
      "dividend": 9.40,
      "workingCapital": -30009000000,
      "totalEquity": 106561000000,
      "retainedEarnings": 104839000000,
      "currency": "DKK"
    },
    "2022": {
      "revenue": 176954000000,
      "grossProfit": 148530000000,
      "operatingIncome": 75618000000,
      "netIncome": 55525000000,
      "freeCashFlow": 66741000000,
      "operatingCashFlow": 78887000000,
      "capex": 12146000000,
      "totalAssets": 241257000000,
      "totalDebt": 25784000000,
      "cashAndEquivalents": 23574000000,
      "shareholdersEquity": 83486000000,
      "bookValuePerShare": 18.55,
      "eps": 12.26,
      "dividend": 6.20,
      "workingCapital": -12746000000,
      "totalEquity": 83486000000,
      "retainedEarnings": 80587000000,
      "currency": "DKK"
    },
    "2021": {
      "revenue": 140800000000,
      "grossProfit": 117142000000,
      "operatingIncome": 59217000000,
      "netIncome": 47757000000,
      "freeCashFlow": 48665000000,
      "operatingCashFlow": 55000000000,
      "capex": 6335000000,
      "totalAssets": 194508000000,
      "totalDebt": 26645000000,
      "cashAndEquivalents": 17485000000,
      "shareholdersEquity": 70746000000,
      "bookValuePerShare": 15.52,
      "eps": 10.40,
      "dividend": 5.20,
      "workingCapital": -13921000000,
      "totalEquity": 70746000000,
      "retainedEarnings": 72004000000,
      "currency": "DKK"
    },
    "2020": {
      "revenue": 126946000000,
      "grossProfit": 106014000000,
      "operatingIncome": 54126000000,
      "netIncome": 42138000000,
      "freeCashFlow": 46126000000,
      "operatingCashFlow": 51951000000,
      "capex": 5825000000,
      "totalAssets": 144922000000,
      "totalDebt": 10356000000,
      "cashAndEquivalents": 12757000000,
      "shareholdersEquity": 63325000000,
      "bookValuePerShare": 13.69,
      "eps": 9.03,
      "dividend": 4.55,
      "workingCapital": -4464000000,
      "totalEquity": 63325000000,
      "retainedEarnings": 63774000000,
      "currency": "DKK"
    }
  },

  "keyRatios": {
    "profitabilityRatios": {
      "grossMargin": 0.8465,
      "operatingMargin": 0.4843,
      "netMargin": 0.3451,
      "roe": 0.8811,
      "roa": 0.2329,
      "roic": 0.4791
    },
    "liquidityRatios": {
      "currentRatio": 0.74,
      "quickRatio": 0.54,
      "cashRatio": 0.176
    },
    "leverageRatios": {
      "debtToEquity": 0.86,
      "debtToAssets": 0.243,
      "interestCoverage": 41.95,
      "debtToEbitda": 0.76
    },
    "valuationRatios": {
      "peRatio": 18.96,
      "forwardPE": 15.43,
      "pbRatio": 14.32,
      "psRatio": 6.54,
      "evToEbitda": 13.31,
      "evToSales": 6.82,
      "pegRatio": null,
      "priceToFcf": 23.32
    },
    "efficiencyRatios": {
      "assetTurnover": 0.77,
      "inventoryTurnover": 1.22,
      "receivablesTurnover": 4.37
    },
    "dataNote": "Ratios based on TTM data as of Q2 2025"
  },

  "growthMetrics": {
    "revenueGrowth5Y": 0.189,
    "epsGrowth5Y": 0.211,
    "fcfGrowth5Y": 0.115,
    "dividendGrowth5Y": 0.201,
    "dividendGrowthStreak": 5
  },

  "dividendInfo": {
    "currentAnnualDividend": 11.40,
    "currentAnnualDividendUSD": 1.18,
    "currentDividendYield": 0.0184,
    "payoutFrequency": "Semi-Annual",
    "payoutRatio": 0.3473,
    "dividendGrowthRate": 0.21,
    "consecutiveYearsOfGrowth": 5,
    "buybackYield": 0.0061,
    "shareholderYield": 0.0244,
    "nextExDividendDate": "2025-08-16",
    "nextPaymentDate": "2025-08-26",
    "dividendPolicy": "Novo Nordisk aims to increase dividend annually in Danish kroner and targets a payout ratio of 40-60% of net profit, taking into account long-term cash flow generation and capital allocation priorities.",
    "aristocratStatus": false,
    "aristocratSince": null,
    "currencyNote": "Dividends declared in DKK, converted to USD at current exchange rates for reference",
    "recentDividendHistory": [
      {
        "year": 2025,
        "quarters": [
          {
            "quarter": "Q3",
            "exDate": "2025-08-16",
            "payDate": "2025-08-26",
            "amountDKK": null,
            "amountUSD": null,
            "status": "upcoming"
          },
          {
            "quarter": "Q1",
            "exDate": "2025-03-31",
            "payDate": "2025-04-08",
            "amountDKK": 5.65,
            "amountUSD": 0.82,
            "status": "paid"
          }
        ],
        "annualTotalDKK": 11.40,
        "annualTotalUSD": 1.18
      },
      {
        "year": 2024,
        "quarters": [
          {
            "quarter": "Q3",
            "exDate": "2024-08-16",
            "payDate": "2024-08-26",
            "amountDKK": 2.50,
            "amountUSD": 0.36,
            "status": "paid"
          },
          {
            "quarter": "Q1",
            "exDate": "2024-03-22",
            "payDate": "2024-04-02",
            "amountDKK": 4.58,
            "amountUSD": 0.66,
            "status": "paid"
          }
        ],
        "annualTotalDKK": 11.40,
        "annualTotalUSD": 1.02
      },
      {
        "year": 2023,
        "quarters": [
          {
            "quarter": "Q3",
            "exDate": "2023-08-18",
            "payDate": "2023-08-29",
            "amountDKK": 2.15,
            "amountUSD": 0.31,
            "status": "paid"
          },
          {
            "quarter": "Q1",
            "exDate": "2023-03-24",
            "payDate": "2023-04-04",
            "amountDKK": 2.92,
            "amountUSD": 0.42,
            "status": "paid"
          }
        ],
        "annualTotalDKK": 9.40,
        "annualTotalUSD": 0.73
      }
    ],
    "dividendGrowthAnalysis": {
      "growthRate1Y": 0.2128,
      "growthRate3Y": 0.242,
      "growthRate5Y": 0.201,
      "growthRate10Y": 0.152,
      "compoundAnnualGrowthRate": 0.205,
      "averageAnnualIncrease": 1.85,
      "consecutiveIncreases": 5,
      "lastCut": "2016 (due to currency effects)",
      "sustainabilityScore": "High"
    },
    "dividendMetrics": {
      "earningsCoverage": 2.88,
      "freeCashFlowCoverage": 2.06,
      "debtServiceCoverage": 35.2,
      "dividendToFcfRatio": 0.485,
      "retentionRatio": 0.653,
      "sustainableDividendGrowth": 0.185,
      "impliedGrowthRate": 0.195
    },
    "peerComparison": {
      "industryAverageDividendYield": 0.022,
      "industryAveragePayoutRatio": 0.42,
      "industryAverageGrowthRate": 0.085,
      "relativeYieldRanking": "Below Average",
      "relativeGrowthRanking": "Excellent",
      "reliabilityRanking": "Very Good"
    }
  },

  "industryBenchmarks": {
    "averagePE": 25.2,
    "averagePB": 4.8,
    "averageROE": 0.18,
    "averageDebtToEquity": 0.65,
    "averageRevGrowth": 0.08,
    "averageDividendYield": 0.022
  },

  "assumptions": {
    "terminalGrowthRate": 0.025,
    "growthPeriodYears": 10,
    "fadeYears": 5,
    "taxRate": 0.209,
    "reinvestmentRate": 0.45,
    "dividendGrowthRate": 0.06,
    "perpetualGrowthRate": 0.025,
    "dividendAssumptions": {
      "targetPayoutRatio": 0.50,
      "minimumPayoutRatio": 0.40,
      "maximumPayoutRatio": 0.60,
      "expectedDividendGrowth": 0.06,
      "conservativeDividendGrowth": 0.08,
      "optimisticDividendGrowth": 0.20,
      "sustainabilityThreshold": 0.70,
      "cyclicalAdjustment": false,
      "variableDividendPolicy": false,
      "shareRepurchasePriority": "Balanced with dividend",
      "specialDividendPotential": false,
      "currencyHedging": true,
      "currencyNote": "Dividends paid in DKK, subject to currency exchange rate fluctuations for USD investors"
    }
  },

  "businessSegments": {
    "diabetesAndObesityCare": {
      "revenue": 284270000000,
      "operatingIncome": 134750000000,
      "description": "Diabetes care products including insulin and GLP-1 treatments, plus obesity treatments like Wegovy",
      "growthRate": 0.2631,
      "marketPosition": "Global leader in diabetes care and emerging leader in obesity treatment"
    },
    "rareDisease": {
      "revenue": 18870000000,
      "operatingIncome": 536000000,
      "description": "Treatments for rare blood disorders and rare endocrine diseases",
      "growthRate": 0.1121,
      "marketPosition": "Established player with specialized treatments"
    }
  },

  "geographicRevenue": {
    "northAmerica": {
      "revenue": 183210000000,
      "percentage": 0.604,
      "growthRate": 0.2496,
      "description": "United States and Canada - largest market driven by GLP-1 demand"
    },
    "international": {
      "revenue": 119930000000,
      "percentage": 0.396,
      "growthRate": 0.2284,
      "description": "Europe, Asia-Pacific, and other international markets"
    }
  },

  "competitivePosition": {
    "marketLeadership": "Global leader in diabetes care, emerging leader in obesity treatment",
    "keyProducts": ["Ozempic", "Wegovy", "Rybelsus", "Tresiba", "Levemir", "NovoRapid"],
    "competitiveAdvantages": [
      "Strong R&D pipeline in GLP-1 and diabetes treatments",
      "Global manufacturing and distribution network",
      "Strong regulatory expertise and track record",
      "Leading position in fast-growing obesity treatment market"
    ],
    "risks": [
      "Patent cliff risks for older diabetes products",
      "Intense competition in GLP-1 space from Eli Lilly",
      "Pricing pressure from healthcare systems",
      "Regulatory scrutiny on drug pricing",
      "Currency exposure for global operations"
    ]
  }
}
